| Luspatercept in patients with lower-risk myelodysplastic syndromes P Fenaux, U Platzbecker, GJ Mufti, G Garcia-Manero, R Buckstein, ... New England Journal of Medicine 382 (2), 140-151, 2020 | 451 | 2020 |
| Phase 2 trial of CPX-351, a fixed 5: 1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML JE Lancet, JE Cortes, DE Hogge, MS Tallman, TJ Kovacsovics, ... Blood, The Journal of the American Society of Hematology 123 (21), 3239-3246, 2014 | 364 | 2014 |
| Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes DA Sallman, AE DeZern, G Garcia-Manero, DP Steensma, GJ Roboz, ... Journal of clinical oncology 39 (14), 1584, 2021 | 348 | 2021 |
| Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology PL Greenberg, RM Stone, A Al-Kali, SK Barta, R Bejar, JM Bennett, ... Journal of the National Comprehensive Cancer Network 15 (1), 60-87, 2017 | 325 | 2017 |
| The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype AA Basiorka, KL McGraw, EA Eksioglu, X Chen, J Johnson, L Zhang, ... Blood, The Journal of the American Society of Hematology 128 (25), 2960-2975, 2016 | 323 | 2016 |
| A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis F Passamonti, T Giorgino, B Mora, P Guglielmelli, E Rumi, M Maffioli, ... Leukemia 31 (12), 2726-2731, 2017 | 313 | 2017 |
| Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study NK Gillis, M Ball, Q Zhang, Z Ma, YL Zhao, SJ Yoder, ME Balasis, ... The lancet oncology 18 (1), 112-121, 2017 | 287 | 2017 |
| Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia E Carballido, M Veliz, R Komrokji, J Pinilla-Ibarz Cancer Control 19 (1), 54-67, 2012 | 265 | 2012 |
| Myelodysplastic syndromes PL Greenberg, E Attar, JM Bennett, CD Bloomfield, CM De Castro, ... Journal of the National Comprehensive Cancer Network 9 (1), 30-56, 2011 | 260 | 2011 |
| SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS L Malcovati, K Stevenson, E Papaemmanuil, D Neuberg, R Bejar, ... Blood, The Journal of the American Society of Hematology 136 (2), 157-170, 2020 | 239 | 2020 |
| Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes MM Patnaik, E Padron, RR LaBorde, TL Lasho, CM Finke, CA Hanson, ... Leukemia 27 (7), 1504-1510, 2013 | 225 | 2013 |
| TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups D Haase, KE Stevenson, D Neuberg, JP Maciejewski, A Nazha, ... Leukemia 33 (7), 1747-1758, 2019 | 217 | 2019 |
| Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes DA Sallman, R Komrokji, C Vaupel, T Cluzeau, SM Geyer, KL McGraw, ... Leukemia 30 (3), 666-673, 2016 | 216 | 2016 |
| Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des Myélodysplasies (GFM) T Cluzeau, M Sebert, R Rahmé, S Cuzzubbo, J Lehmann-Che, ... Journal of Clinical Oncology 39 (14), 1575, 2021 | 203 | 2021 |
| Male breast cancer in the veterans affairs population: a comparative analysis ZA Nahleh, R Srikantiah, M Safa, AR Jazieh, A Muhleman, R Komrokji Cancer: Interdisciplinary International Journal of the American Cancer …, 2007 | 202 | 2007 |
| The first-in-class anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in MDS and AML patients: ongoing phase 1b results DA Sallman, AS Asch, MM Al Malki, DJ Lee, WB Donnellan, G Marcucci, ... Blood 134, 569, 2019 | 198 | 2019 |
| An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults MR Savona, L Malcovati, R Komrokji, RV Tiu, TI Mughal, A Orazi, ... Blood, The Journal of the American Society of Hematology 125 (12), 1857-1865, 2015 | 182 | 2015 |
| Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN E Jabbour, NJ Short, G Montalban-Bravo, X Huang, C Bueso-Ramos, ... Blood, The Journal of the American Society of Hematology 130 (13), 1514-1522, 2017 | 177 | 2017 |
| GM-CSF–dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia E Padron, JS Painter, S Kunigal, AW Mailloux, K McGraw, JM McDaniel, ... Blood, The Journal of the American Society of Hematology 121 (25), 5068-5077, 2013 | 171 | 2013 |
| Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes MA Sekeres, RV Tiu, R Komrokji, J Lancet, AS Advani, M Afable, ... Blood, The Journal of the American Society of Hematology 120 (25), 4945-4951, 2012 | 165 | 2012 |
